Financial Results and Operational Highlights for the Third Quarter Ended March 31, 2018
May 30, 2018 19:32 ET
|
Mesoblast Limited
MELBOURNE, Australia and NEW YORK, May 30, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced strong financial results for the nine months ended March 31, 2018 and...
Mesoblast Appoints New Chief Financial Officer
May 30, 2018 18:41 ET
|
Mesoblast Limited
MELBOURNE, Australia and NEW YORK, May 30, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced the appointment of Josh Muntner as its new Chief Financial Officer,...
Mesoblast Financial Results Webcast for Quarter Ended March 31, 2018
May 29, 2018 15:21 ET
|
Mesoblast Limited
NEW YORK and MELBOURNE, Australia, May 29, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) will report financial results for the quarter ended March 31, 2018 in a webcast...
Mesoblast Partners With Cartherics to Develop ’off-the-shelf’ Cell-based Immunotherapies for Solid Cancers
May 29, 2018 06:00 ET
|
Mesoblast Limited
NEW YORK and MELBOURNE, Australia, May 29, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that it has entered into a partnership with Cartherics Pty Ltd to...
Mesoblast Phase 3 Trial Results for Acute Graft Versus Host Disease Presented at 2018 International Society for Cell and Gene Therapy Annual Meeting
May 08, 2018 06:00 ET
|
Mesoblast Limited
NEW YORK and MELBOURNE, Australia, May 08, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that results of the Phase 3 trial evaluating its product candidate...
Mesoblast Cell Therapies Featured at Vatican International Healthcare Conference
May 01, 2018 06:00 ET
|
Mesoblast Limited
NEW YORK and MELBOURNE, Australia, May 01, 2018 (GLOBE NEWSWIRE) -- Mesoblast’s proprietary allogeneic cell technology platform was featured at the Unite to Cure Fourth International Vatican...
Mesoblast Clinical Program Update for MPC-150-IM in Patients With Chronic Heart Failure
April 18, 2018 06:00 ET
|
Mesoblast Limited
NEW YORK and MELBOURNE, Australia, April 18, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today provided an update on the Phase 3 and Phase 2b clinical trials of the Company's...
Mesoblast Phase 3 Cell Therapy Trial for Chronic Low Back Pain Completes Enrollment
March 28, 2018 18:25 ET
|
Mesoblast Limited
NEW YORK and MELBOURNE, Australia, March 28, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced that enrollment has completed in the Phase 3 trial evaluating a single...
Mesoblast Enters Into US$75 Million Non-Dilutive Credit Facility
March 06, 2018 19:31 ET
|
Mesoblast Limited
MELBOURNE, Australia and NEW YORK, March 06, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced that it has entered into a US$75 million non-dilutive, four-year...
Mesoblast Operational Highlights and Financial Results for the Half-Year Ended December 31, 2017
February 27, 2018 16:47 ET
|
Mesoblast Limited
MELBOURNE, Australia and NEW YORK, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today provided the market with an update on its operational highlights and consolidated...